Phase Ib/Ii Study to Evaluate Safety and Efficacy of Debio 0123 and Sacituzumab Govitecan in TNBC or HRHER2- Advanced/ Metastatic Breast Cancer (Win-B)

2024-516322-60-00 Protocol MEDOPP0621 Phase I and Phase II (Integrated) - Other Temporarily halted

Start 17 Jan 2025 · Status Temporarily halted · 1 EU/EEA countries · 9 sites · Protocol MEDOPP0621

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Temporarily halted
Participants planned 40
Countries 1
Sites 9

TRIPLE-NEGATIVE OR HR+/HER2– ADVANCED/METASTATIC BREAST CANCER

Key facts

Sponsor
Medica Scientia Innovation Research S.L.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
17 Jan 2025 → ongoing
Decision date (initial)
2024-11-07
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516322-60-00
ClinicalTrials.gov
NCT06612203

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

TRIPLE-NEGATIVE OR HR+/HER2– ADVANCED/METASTATIC BREAST CANCER

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Medica Scientia Innovation Research S.L.

Sponsor organisation
Medica Scientia Innovation Research S.L.
Address
Carrer De Pere IV 128 3rd Floor
City
Barcelona
Postcode
08005
Country
Spain

Scientific contact point

Organisation
Medica Scientia Innovation Research S.L.
Contact name
Alicia Garcia

Public contact point

Organisation
Medica Scientia Innovation Research S.L.
Contact name
Meritxell Aguiló García

Locations

1 EU/EEA country · 9 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Temporarily halted 40 9
Rest of world 0

Investigational sites

Spain

9 sites · Temporarily halted
Hospital Clinico Universitario De Valencia
Medical Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario 12 De Octubre
Medical Oncology, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitario Marques De Valdecilla
Medical Oncology, Avenida Valdecilla Sn, 39008, Santander
Hospital Universitari Dexeus Grupo Quironsalud
Medical Oncology, Calle De Sabino Arana 5-19, 08028, Barcelona
Hospital Arnau De Vilanova De Valencia
Medical Oncology, Calle De San Clemente 12, 46015, Valencia
Hospital Beata Maria Ana
Medical Oncology, Calle Del Doctor Esquerdo No. 83, 28007, Madrid
Hospital Universitario Virgen De La Victoria
Medical Oncology, Calle Del Arroyo Teatinos S/N, 29010, Malaga
Hospital Del Mar
Medical Oncology, Passeig Maritim De La Barceloneta 25-29, 08003, Barcelona
Institut Catala D'oncologia
Medical Oncology, Avinguda De Franca S/n, 17007, Girona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-01-17 2025-02-06 2025-11-06

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-107349

Halt date
2025-11-06
Planned restart
2026-04-30
Member states concerned
Spain
Publication date
2025-11-20
Reason
Safety related (clinical or pre-clinical results)
Explanation
This decision follows the outcome of the Study Steering Committee meeting held on 06/11/2025, during which the Committee recommended implementing additional measures to better characterize study pharmacokinetic and pharmacodynamic data for the combination. These recommendations will be incorporated into the corresponding protocol amendment and applied to newly enrolled patients.
Follow-up measures
Protocol amendment will be developed to implement additional safety measures with the aim of improving patient’s safety.
There is 1 patient ongoing, and since the patient is receiving the first level dose, the patient will continue with the treatment with no changes.
Benefit-risk balance changed
Yes
Treatment stopped
No

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-14 Spain Acceptable
2024-11-06
2024-11-07
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-07-02 Spain Acceptable
2024-11-06
2025-07-02
3 SUBSTANTIAL MODIFICATION SM-1 2025-08-08 Spain Acceptable
2025-10-13
2025-10-30